Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
RCT
ACE Report #4725
Ace Report Cover Osteoarthritis

Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis

J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5

Contributing Authors: JS Hwang LS Chin JF Chen TS Yang PQ Chen KS Tsai PC Leung

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

323 Chinese women were randomized to evaluate the efficacy and safety of a once-yearly zoledronic acid treatment for postmenopausal osteoporosis. Patients received either annual infusions of zoledronic acid or placebo for 3 consecutive years and were assessed at the end of this period. Results revealed that zoledronic acid reduced the risk of vertebral fractures and increased the bone mineral dens...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.